Report Details:
15 Companies Covered
128 Pages
Artificial Tears Market Highlights
Artificial Tears Market Size was estimated at 3.503 USD Billion in 2024. The Artificial Tears industry is projected to grow from USD 3.73 Billion in 2025 to USD 6.991 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.48% during the forecast period 2025 - 2035.
In recent years, many objective and quantitative diagnostic methods for evaluating dry eye diseases such as tear quality metrics, tear quantity metrics, and ocular surface structural analysis have been developed. There are several products available in the market such as I-Pen Tear Osmolarity System (I-Med Pharma, Canada), Inflammadry (Quidel, US), TearLab Osmolarity System (TearLab US), and Cirrus (Carl Zeiss AG, Germany).
Likewise, there have been significant advancements in diagnostic technology which are anticipated to promote medical screening for the Dry Eye Disease (DED.) The companies are actively developing new technologies to enhance their portfolio for DED diagnostics.
For instance, in August 2021, AXIM Biotechnologies, Inc. (US) entered into an agreement with Advanced Tear Diagnostics (US) to acquire the technology for DED testing. Thus, the technological advancements in diagnostic testing are likely to create lucrative growth opportunities for the artificial tears market players during the forecast period.
The increasing prevalence of dry eye disease and eye inflammation, and rising preference for preservative-free products are propelling the market growth. However, the side effects and allergic reactions are expected to hamper the growth of the global market. Nevertheless, advancements in diagnostics for dry eye disease are projected to create lucrative opportunities for market players.
Key Players
MRFR recognizes the following companies as the key players in the global artificial tears market— Johnson and Johnson Vision Care (US), Allergan plc (Ireland), Alcon Plc (Switzerland), Bausch & Lomb Incorporated (Canada), Santen, Inc (Japan), URSAPHARM Arzneimittel GmbH (Germany), ROHTO Pharmaceutical CO., LTD (Japan), Similasan Corporation (US), Ocusoft (US), and Nicox (France).
Segment Analysis
The global artificial tears market has been segmented based on type, delivery mode, application, and distribution channel.
On the basis of type, the market is segmented into polyethylene glycol, propylene glycol, cellulose, glycerin, and others. The glycerin segment was attributed to holding the largest market share of over 30.31% in 2022 revenue as estimated by MRFR analysts. This is due to the rising older population and the innovations in the product range, and various benefits associated with the use of products.
Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new service launches.
Based on delivery mode, the global artificial tears market has been segmented into eye drops, ointments, and sprays. The eye drops segment was expected to hold the largest market share in 2022.
On the basis of the application, the market is segmented into dry eye syndrome, allergies and infections, and others. The dry eye syndrome segment is projected to have the largest market share during the forecast period.
On the basis of the distribution channel, the market is segmented into hospital pharmacies, drug stores retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to have the largest market share during the forecast period.
Regional Analysis
The global artificial tears market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe artificial tears market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The artificial tears market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s artificial tears market comprises of Middle East, Africa, and Latin America.
the rising number of people with refractive errors and increasing awareness of refractive vision correction leads to demand for contact lenses are also expected to foster North America’s market growth.
Moreover, the Europe market has been persistently growing owing to a rapidly surging aging population and the increasing prevalence of ophthalmic disorders creates a demand for artificial tears in the region.
Additionally, market factors, such as growing awareness of ocular illnesses, increasing population and aging people, and rising awareness of ocular diseases in the Asia-Pacific region and are driving the region’s growth.
Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of the artificial tears market in the region are the improving healthcare infrastructure and increasing government initiatives, improvements in developing their health systems, and improving the health status of their populations.
Key Findings of the Study
- The rise in digital eye strain is significantly influencing the demand for artificial tears, particularly in North America.
- Preservative-free formulations are increasingly preferred by consumers, reflecting a shift towards safer eye care options in the Asia-Pacific region.
- Technological advancements in product formulations are enhancing the efficacy and appeal of artificial tears, especially in the polyethylene glycol segment.
- The increase in the aging population and rising awareness of eye health are major drivers propelling market growth, particularly in the eye drops segment.
